Noteworthy ETF Outflows: VXF, CRH, APO, WDAY
ETF Price Range: VXF's share price has a 52-week range of $137.74 to $194.99, with the last trade at $194.86, indicating it is near its high point.
ETF Trading Dynamics: ETFs function like stocks but involve trading units that can be created or destroyed based on investor demand, impacting the underlying assets held within them.
Trade with 70% Backtested Accuracy
Analyst Views on VXF
About the author
VELO Stock Surges Over 20% Following Major Debt Cut — Retail Investors Applaud Insider Trust
Debt Conversion: Velo 3D's CEO and a director converted significant debt into equity, reducing the company's outstanding debt by 60% to approximately $10 million, while shares were trading around $14.50.
Market Reaction: Following the debt conversion, Velo's stock saw a notable increase of over 20%, reflecting positive retail investor sentiment and confidence in the company's future.
CEO's Investment: Dr. Arjun Jeldi, the CEO, purchased a $5 million promissory note and converted it into common stock at a premium price of $16.38 per share, indicating strong belief in the company's long-term value.
Stock Performance: Velo's stock has gained over 408% in the past year, while the 3D Printing ETF has increased by about 7.5%, showcasing a robust performance in the sector.
ATOS Shares Plunge 32% — Retail Investors Weigh In on the Reverse Stock Split
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.
Cathie Wood Continues Acquiring CoreWeave Stock (CRWV): Analyzing the Major Stakeholders
ARK Invest's Stake in CoreWeave: Cathie Wood's ARK Invest has significantly increased its investment in CoreWeave, purchasing over 800,000 shares worth approximately $59.5 million despite a recent decline in the stock price due to Nvidia GPU reliance concerns.
Long-Term Confidence in AI Growth: The continued purchases reflect ARK's confidence in CoreWeave's long-term growth potential, driven by increasing demand for AI computing power and new contracts with major tech firms, even as the stock has dropped nearly 48% in the past month.
Ownership Breakdown: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, followed by Philippe Laffont at 4.68%.
Analyst Ratings and Price Target: Analysts have a Moderate Buy consensus on CoreWeave, with 12 Buys, 11 Holds, and one Sell, and an average price target of $148.32 per share, indicating a potential upside of about 108%.
Examining CoreWeave Stock (CRWV) Ownership Before Q3 Earnings
CoreWeave Q3 Results Announcement: CoreWeave is set to announce its third-quarter results on November 10, with expectations of a loss per share of $0.40 on revenue of $1.29 billion, despite a strong year-over-year revenue growth of 207% in Q2 2025.
Stock Performance and Analyst Sentiment: Despite a recent pullback in shares and concerns over high debt and customer concentration, CoreWeave's stock is up 168% from its IPO price, with analysts maintaining a Moderate Buy consensus rating and a price target indicating 46% upside potential.
Partnership with Vast Data: Ahead of the Q3 results, CoreWeave announced a $1.17 billion commercial agreement with AI startup Vast Data, reflecting the growing demand for AI infrastructure.
Ownership Structure: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, while various ETFs and mutual funds also hold minor stakes in the company.
ETF Fundamental Report for VXF
Vanguard Extended Market ETF Overview: The Vanguard Extended Market ETF (VXF) is a Mid-Cap Value ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Factor Analysis: The report provides a detailed analysis of VXF's exposure to key investing factors such as value, quality, momentum, and low volatility, scoring from 1 to 99.
Vanguard Extended Market (VXF) Shares Cross Above 200 DMA
VXF Performance Overview: VXF's 52-week low is $146.68 and its high is $207.77, with the last trade recorded at $185.98.
Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
VELO Stock Surges Over 20% Following Major Debt Cut — Retail Investors Applaud Insider Trust
Debt Conversion: Velo 3D's CEO and a director converted significant debt into equity, reducing the company's outstanding debt by 60% to approximately $10 million, while shares were trading around $14.50.
Market Reaction: Following the debt conversion, Velo's stock saw a notable increase of over 20%, reflecting positive retail investor sentiment and confidence in the company's future.
CEO's Investment: Dr. Arjun Jeldi, the CEO, purchased a $5 million promissory note and converted it into common stock at a premium price of $16.38 per share, indicating strong belief in the company's long-term value.
Stock Performance: Velo's stock has gained over 408% in the past year, while the 3D Printing ETF has increased by about 7.5%, showcasing a robust performance in the sector.
ATOS Shares Plunge 32% — Retail Investors Weigh In on the Reverse Stock Split
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.
Cathie Wood Continues Acquiring CoreWeave Stock (CRWV): Analyzing the Major Stakeholders
ARK Invest's Stake in CoreWeave: Cathie Wood's ARK Invest has significantly increased its investment in CoreWeave, purchasing over 800,000 shares worth approximately $59.5 million despite a recent decline in the stock price due to Nvidia GPU reliance concerns.
Long-Term Confidence in AI Growth: The continued purchases reflect ARK's confidence in CoreWeave's long-term growth potential, driven by increasing demand for AI computing power and new contracts with major tech firms, even as the stock has dropped nearly 48% in the past month.
Ownership Breakdown: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, followed by Philippe Laffont at 4.68%.
Analyst Ratings and Price Target: Analysts have a Moderate Buy consensus on CoreWeave, with 12 Buys, 11 Holds, and one Sell, and an average price target of $148.32 per share, indicating a potential upside of about 108%.
Examining CoreWeave Stock (CRWV) Ownership Before Q3 Earnings
CoreWeave Q3 Results Announcement: CoreWeave is set to announce its third-quarter results on November 10, with expectations of a loss per share of $0.40 on revenue of $1.29 billion, despite a strong year-over-year revenue growth of 207% in Q2 2025.
Stock Performance and Analyst Sentiment: Despite a recent pullback in shares and concerns over high debt and customer concentration, CoreWeave's stock is up 168% from its IPO price, with analysts maintaining a Moderate Buy consensus rating and a price target indicating 46% upside potential.
Partnership with Vast Data: Ahead of the Q3 results, CoreWeave announced a $1.17 billion commercial agreement with AI startup Vast Data, reflecting the growing demand for AI infrastructure.
Ownership Structure: Public companies and individual investors hold 76.58% of CoreWeave, with CW Opportunity LLC being the largest shareholder at 7.77%, while various ETFs and mutual funds also hold minor stakes in the company.
ETF Fundamental Report for VXF
Vanguard Extended Market ETF Overview: The Vanguard Extended Market ETF (VXF) is a Mid-Cap Value ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Factor Analysis: The report provides a detailed analysis of VXF's exposure to key investing factors such as value, quality, momentum, and low volatility, scoring from 1 to 99.
Vanguard Extended Market (VXF) Shares Cross Above 200 DMA
VXF Performance Overview: VXF's 52-week low is $146.68 and its high is $207.77, with the last trade recorded at $185.98.
Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
